VCEL Vericel Corporation

ANN ARBOR, Mich., March 9 /PRNewswire-FirstCall/ -- Aastrom Biosciences, Inc. (NASDAQ:ASTM), a company developing cell-based therapeutics for regenerative medicine, today announced that Gerald D. Brennan, Jr., Vice President, Administrative & Financial Operations and Chief Financial Officer will present at the Cowen & Company 27th Annual Health Care Conference on Wednesday, March 14, 2007 at 8:00am (EST). The conference will be held March 12-15th at the Boston Marriott Copley Place Hotel in Boston, MA. (Logo: http://www.newscom.com/cgi-bin/prnh/20070117/CLW099LOGO ) A live webcast of Aastrom's presentation can be accessed by logging onto Aastrom's website at http://www.aastrom.com/. A replay of the presentation will be archived for 2 weeks. About Aastrom Biosciences, Inc. Aastrom Biosciences, Inc. develops autologous cell products for the repair or regeneration of multiple human tissues, based on its proprietary Tissue Repair Cell (TRC) technology. Aastrom's TRC-based products are a unique cell mixture containing stem and progenitor cell populations, produced from a small amount of bone marrow taken from the patient. TRC-based products have been used in over 240 patients, and are currently in clinical trials for bone regeneration (osteonecrosis of the femoral head, long bone fractures and spine fusion) and vascular regeneration (critical limb ischemia) applications. Aastrom has reported positive interim clinical trial results for TRCs suggesting both the clinical safety and the ability of TRCs to promote healing in bone regeneration applications. The Company is also developing programs for TRC-based therapies to address cardiac and neural regeneration indications. TRCs have received Orphan Drug Designation from the FDA for use in the treatment of osteonecrosis of the femoral head and the treatment of dilated cardiomyopathy, a severe chronic disease of the heart. For more information, visit Aastrom's website at http://www.aastrom.com/. (astmc) This document contains forward-looking statements, including without limitation, statements regarding product development objectives, market development plans, and potential advantages and applications of Tissue Repair Cells, which involve certain risks and uncertainties. The forward-looking statements are also identified through use of the words "plans," and other words of similar meaning. Actual results may differ significantly from the expectations contained in the forward-looking statements. Among the factors that may result in differences are the results obtained from clinical trial activities, regulatory approval requirements, and the availability of resources. These and other significant factors are discussed in greater detail in Aastrom's Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. CONTACTS: Kris M. Maly Cameron Associates Investor Relations Department Kevin McGrath Aastrom Biosciences, Inc. Phone: (212) 245-4577 Phone: (734) 930-5777 Deanne Eagle (Media) Phone: (212) 554-5463 http://www.newscom.com/cgi-bin/prnh/20070117/CLW099LOGO http://photoarchive.ap.org/ DATASOURCE: Aastrom Biosciences, Inc. CONTACT: Kris M. Maly of Aastrom Biosciences, Inc., +1-734-930-5777; or Kevin McGrath, +1-212-245-4577, or Deanne Eagle, +1-212-554-5463, both of Cameron Associates, for Aastrom Biosciences, Inc. Web site: http://www.aastrom.com/

Copyright